Join the Conversation: AMCP Metabolic Health LINK Interest Group
The AMCP Metabolic Health LINK was created to help managed care pharmacy professionals stay connected as new evidence, treatments, and care models continue to emerge. Through webinars, peer discussions, and collaborative learning opportunities, LINK participants can exchange ideas, discuss real-world challenges, and explore practical approaches to improving outcomes across obesity, diabetes, cardiovascular disease, kidney disease, and related conditions.
Get involved by attending the upcoming webinar, Leading the Transformation of the Metabolic Health Crisis, on October 6. The session will examine the new 2026 cardiovascular-kidney-metabolic guideline and what it means for managed care pharmacy.
Join the LINK
(AMCP Membership Required)
The Solution
AMCP has launched a strategic initiative to empower payers to shift from siloed, condition-specific care to holistic root cause-focused metabolic health management that coordinates across related conditions. Starting with the new ADA 2026 CGM expansions that are reshaping coverage and access, AMCP aims to redefine roles in benefit design and population outcomes.
Key Deliverables to Support Decision-Making
Explore Metabolic Resources
Featured JMCP Articles & Education
BACKGROUND: Treatment adherence and persistence are crucial to achieve glycemic control in patients with type 2 diabetes (T2D).
BACKGROUND: Type 2 diabetes (T2D) is characterized by chronic hyper-glycemia and can lead to life-threatening complications if not treated. A stepwise and patient-centered approach is recommended when managing patients with T2D.
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of atherosclerotic cardiovascular (ASCVD) disease, which is the largest contributor to the economic burden of diabetes.
BACKGROUND: Because of improved clinical outcomes, recent American Diabetes Association guidelines recommend the use of newer antidiabetic agents—glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i)—by those with cardiovascular disease.
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are recommended as add-on therapy in patients with uncontrolled type 2 diabetes (T2D), with no specific guidance as to timing versus insulin.
BACKGROUND: Cardiovascular disease (CVD), which affects 79.4 million Americans, is a relentless problem that continues to grow by leaps and bounds.
OBJECTIVE: To review current perspectives on hypertension and metabolic syndrome.
SUMMARY: Hypertension can be considered a national burden: 1 in 3 Ame
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
